EIM
AVEO

Essex Investment Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Essex Investment Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21,635
Closed -$627K – 442
2018
Q1 		$627K Buy
21,635
+1,435
+7% +$42K 0.08% 252
2017
Q4 		$564K Buy
20,200
+5,138
+34% +$160K 0.07% 265
2017
Q3 		$550K Buy
+15,062
New +$466K 0.07% 253

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Essex Investment Management's AVEO Position: Q2 2018 in Review

Essex Investment Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2018, closing a stake of 21,635 shares — an estimated $627K sold.

Essex Investment Management first reported a position in AVEO in Q3 2017 and held it in 3 quarters. The position peaked at $627K in Q1 2018. 94 funds tracked by Wall St. Rank hold AVEO as of Q2 2018.

  • Essex Investment Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Essex Investment Management sold 21,635 AVEO Pharmaceuticals, Inc. shares in Q2 2018, an estimated $627K.
  • Essex Investment Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
  • Essex Investment Management's AVEO Pharmaceuticals, Inc. position peaked at $627K in Q1 2018.
  • 94 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2018.

Based on Essex Investment Management's 13F filing for Q2 2018, filed 17 Jul 2018.